This phase I trial is comparing two oral drugs (LXH254 and LTT462) in patients with metastatic (KRAS or BRAF) Non-Small Cell (NSC) Lung Cancer.
This trial is treating patients with Non-Small Cell (NSC) Lung Cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ib, Open-label, Multicenter Study of Oral LXH254 in Combination With Oral LTT462 in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer
The purpose of this trial is to characterize safety and tolerability of LXH254 and LTT462 combination and identify a recommended dose and regimen.
Recruiting Hospitals Read More